Update shared on 11 Sep 2025
Fair value Decreased 17%Consensus price targets for Nightingale Health Oyj have been lowered primarily due to sharply reduced revenue growth forecasts and a resulting increase in future P/E, leading to a revised fair value of €2.40 from €2.90.
What's in the News
- Nightingale Health has been selected as the metabolomics analysis provider for the Moli-sani study in Italy, with a contract valued at approximately EUR 728,000 and analysis expected to complete by year-end 2025.
- The company officially opened its fully operational U.S. laboratory at the Alexandria Center for Life Science in New York, offering CoreMetabolomics™, RemoteOmics™, and Multi-omics services to medical research customers, with plans to expand into the healthcare sector.
- South Savo Wellbeing Services County will pilot Nightingale Health's blood analysis technology in primary healthcare, making its disease risk detection test available to over 100,000 people.
Valuation Changes
Summary of Valuation Changes for Nightingale Health Oyj
- The Consensus Analyst Price Target has significantly fallen from €2.90 to €2.40.
- The Consensus Revenue Growth forecasts for Nightingale Health Oyj has significantly fallen from 50.8% per annum to 29.5% per annum.
- The Future P/E for Nightingale Health Oyj has significantly risen from 171.06x to 223.24x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.